Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study For Convivia(TM)
Apr 22nd 2008Drug InformationAlcohol / Addiction / Illegal Drugs
Raptor Pharmaceuticals Corp. (”Raptor” or the “Company”) (OTC Bulletin Board: RPTP), announced that its clinical development subsidiary, Bennu Pharmaceuticals Inc. (”Bennu”), has initiated the Company’s first clinical-stage program after dosing the first cohort in a Phase IIa study of oral 4-methylpyrazole (”4-MP”) in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia(TM) program.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
